6th pilot rapid assessment of WP5 JA2 Strand B on “Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke”
Joint "Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C”
The 5th pilot rapid assessment of WP5 JA2 Strand B on “Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation” is now available.
4th pilot rapid assessment of WP5 JA2 Strand B on “Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenosis”
Joint Assessment on Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)
Joint Assessment on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Joint Assessment on sorafenib (Nexavar®) and its use for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine
3rd Pilot rapid assessment on ‘Balloon Eustachian Tuboplasty for the treatment of Eustachian tube dysfunction'
Fecal Immunochemical Test (FIT) vs guaiac-based fecal occult blood test (FOBT) for colorectal cancer screening (Core HTA 1)
Second pilot rapid assessment on ‘canagliflozin for the treatment of type 2 diabetes mellitus’
Subscribe to our Newsletter
The EUnetHTA JA 2 has received funding from the European Union, in the framework of the Health Programme.